These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. [Recombinant factor VIII. An introduction to recombinant DNA technology and the first results published in the replacement treatment of hemophilia A]. Juárez Giménez JC; Montoro Ronsano JB; Tusell JM Med Clin (Barc); 1994 Nov; 103(15):591-5. PubMed ID: 7990527 [No Abstract] [Full Text] [Related]
67. Hemolytic anemia and F. VIII concentrate. Girelli G Eur J Haematol; 1989 Apr; 42(4):414. PubMed ID: 2498124 [No Abstract] [Full Text] [Related]
68. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Hay CR; Brown S; Collins PW; Keeling DM; Liesner R Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433 [TBL] [Abstract][Full Text] [Related]
69. Million dollar miracles. Smith SD Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280 [No Abstract] [Full Text] [Related]
70. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999. Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744 [No Abstract] [Full Text] [Related]
71. Case report of an inhibitor patient treated with recombinant factor VIII. Kim H Ann Hematol; 1994; 68 Suppl 3():S37. PubMed ID: 8180257 [No Abstract] [Full Text] [Related]
72. Inhibitor to factor VIII in mild haemophilia. Lowe GD; Forbes CD Thromb Haemost; 1985 Feb; 53(1):159. PubMed ID: 3922079 [No Abstract] [Full Text] [Related]
73. Commentary on Brackmann and Gormsen (Lancet 1977; ii: 933): Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lee CA Haemophilia; 2010 May; 16(102):4-5. PubMed ID: 20536981 [No Abstract] [Full Text] [Related]
74. Factor VIII inhibitors in patients with hemophilia A. Oren H; Yaprak I; Irken G Acta Haematol; 1999; 102(1):42-6. PubMed ID: 10473887 [TBL] [Abstract][Full Text] [Related]
75. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Giles AR; Rivard GE; Teitel J; Walker I Transfus Sci; 1998 Jun; 19(2):139-48. PubMed ID: 10187039 [TBL] [Abstract][Full Text] [Related]
76. Use of recombinant factor VIII in the management of hemophilia. Mannucci PM; Gringeri A; Cattaneo M Curr Stud Hematol Blood Transfus; 1991; (58):46-51. PubMed ID: 1954773 [No Abstract] [Full Text] [Related]
78. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective. McDonald JR Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829 [No Abstract] [Full Text] [Related]
79. The past and the future: recombinant factor VIII and the consumer. Isaac BM Transfus Med Rev; 1992 Oct; 6(4):280-3. PubMed ID: 1421830 [No Abstract] [Full Text] [Related]
80. The use of porcine factor VIII in France. Negrier C Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]